hoxa11a Antibody

What is HOXA11 and what are its primary cellular functions in research contexts?

HOXA11 is a homeobox transcription factor that plays a crucial role in embryonic development and cellular differentiation. It functions as a key regulator of gene expression during development, making it a significant target in developmental biology, regenerative medicine, and cancer research . The protein is primarily localized in the nucleus and has a calculated molecular weight of approximately 34kDa, though Western blot detection typically shows bands around 30kDa . HOXA11 contains a sequence corresponding to amino acids 1-180 in humans (NP_005514.1) that is frequently used as an immunogen for antibody production .

In research settings, HOXA11 is studied for its roles in:

• Embryogenesis and tissue patterning

• Cellular differentiation pathways

• Transcriptional regulation networks

• Cancer progression and therapeutic resistance

How do HOXA11 antibodies perform across different experimental applications?

HOXA11 antibodies demonstrate varying performance across experimental platforms:

For Western blot applications, positive control tissues include mouse colon, rat uterus, and rat kidney . Researchers should validate antibody specificity using appropriate positive and negative controls, especially when working with novel tissue types or experimental conditions.

What distinguishes long non-coding RNA HOXA11-AS from HOXA11 protein in research applications?

While HOXA11 antibodies target the protein product, studying HOXA11-AS (antisense RNA) requires different methodological approaches:

• HOXA11 protein detection: Utilizes antibody-based methods such as Western blot, immunofluorescence, or immunohistochemistry

• HOXA11-AS RNA detection: Requires nucleic acid techniques such as qRT-PCR, RNA-FISH, or RNA-seq

HOXA11-AS has been identified as significantly upregulated in ovarian cancer tissues compared to normal controls, with expression levels up to 77-fold higher in epithelial ovarian cancer . Similarly, HOXA11-AS is notably upregulated in glioma tissues . These differential expression patterns make both molecules valuable research targets, though they require distinct detection methodologies.

What methodological considerations are critical when using HOXA11 antibodies in cancer research models?

When designing experiments using HOXA11 antibodies in cancer research, researchers should consider:

Sample preparation optimization:

• For cell lines: Standardize lysis buffers to include phosphatase and protease inhibitors

• For tissue samples: Optimize fixation protocols to preserve epitope accessibility

• For immunoprecipitation: Use gentle detergents (0.1-0.5% NP-40 or Triton X-100) to maintain protein interactions

Expression validation approaches:

• Combine antibody detection with transcript analysis (qRT-PCR)

• Include knockdown/knockout controls to confirm specificity

• Consider antibody validation using mass spectrometry

Research indicates that HOXA11-AS expression increases with ovarian cancer progression and correlates with poor prognosis (log-rank P = 0.00089) . When studying such prognostic relationships, researchers should implement multivariate analysis to account for confounding variables in patient cohorts.

How can contradictions between HOXA11 antibody detection and gene expression data be resolved methodologically?

Discrepancies between protein detection and transcript levels are common challenges that require systematic troubleshooting:

• Technical validation:

  • Test multiple antibody clones targeting different epitopes

  • Employ orthogonal protein detection methods (mass spectrometry)

  • Optimize extraction protocols for different subcellular compartments

• Biological explanations:

  • Assess post-transcriptional regulation (miRNA targeting)

  • Evaluate protein stability and half-life in experimental models

  • Consider post-translational modifications affecting epitope recognition

• Integrated approaches:

  • Implement pulse-chase experiments to track protein turnover

  • Use translational inhibitors to assess protein stability

  • Perform subcellular fractionation to assess compartmentalization

Studies have shown that cisplatin-resistant ovarian cancer cells express significantly higher levels of HOXA11-AS than cisplatin-sensitive cells , highlighting the importance of correlating transcript levels with protein expression when studying drug resistance mechanisms.

What experimental controls are essential when studying HOXA11's role in drug resistance mechanisms?

When investigating HOXA11/HOXA11-AS in drug resistance contexts, implement these critical controls:

Essential experimental controls:

• Paired sensitive/resistant cell line models (e.g., A2780 and A2780/DDP cisplatin-resistant cells)

• Time course analyses to capture dynamic expression changes during resistance development

• Concentration-response curves with standardized viability assays (e.g., CCK-8)

• Genetic manipulation controls (knockdown/overexpression with appropriate vectors)

Mechanistic validation approaches:

• Pathway inhibition studies (e.g., autophagy inhibitor 3-methyladenine as used in HOXA11-AS studies)

• Combination treatment paradigms to assess synergistic effects

• Rescue experiments to confirm specificity of observed phenotypes

Research has demonstrated that HOXA11-AS knockdown significantly increases sensitivity to cisplatin in resistant cell lines and promotes apoptosis, while inhibiting autophagy reverses these effects . Such mechanistic studies require careful control implementation to establish causality.

How can ChIP assays be optimized when using HOXA11 antibodies to study transcriptional targets?

For successful ChIP experiments with HOXA11 antibodies:

• Cross-linking optimization:

  • Test multiple formaldehyde concentrations (0.5-2%)

  • Optimize cross-linking times (10-20 minutes)

  • Consider dual cross-linking approaches for stronger protein-DNA interactions

• Chromatin fragmentation parameters:

  • Target 200-500bp fragments for optimal resolution

  • Validate sonication efficiency via gel electrophoresis

  • Adjust conditions based on cell/tissue type

• Immunoprecipitation considerations:

  • Pre-clear chromatin to reduce background

  • Include IgG negative controls and positive controls (e.g., histone marks)

  • Optimize antibody concentration and incubation conditions

• Data analysis approaches:

  • Normalize to input controls

  • Use appropriate peak calling algorithms

  • Validate binding sites with orthogonal methods (e.g., reporter assays)

HOXA11, as a transcription factor, binds DNA and regulates gene expression during development, making ChIP assays valuable for identifying direct regulatory targets in both normal and pathological contexts.

What methodological approaches can effectively measure HOXA11-AS-mediated autophagy modulation in cancer cells?

Based on research showing HOXA11-AS knockdown increases autophagy in ovarian cancer cells , these methods can effectively measure autophagy modulation:

• Protein marker analysis:

  • Western blot for autophagy markers (LC3-I/II conversion, p62/SQSTM1 degradation)

  • Quantify conversion ratios using densitometry

  • Include lysosomal inhibitors (bafilomycin A1) to assess autophagic flux

• Fluorescence microscopy techniques:

  • Quantify LC3 puncta formation using immunofluorescence

  • Implement tandem fluorescent-tagged LC3 (mRFP-GFP-LC3) to distinguish autophagosomes from autolysosomes

  • Use live-cell imaging to track autophagy dynamics

• Electron microscopy:

  • Visualize ultrastructural features of autophagic vesicles

  • Quantify autophagosome and autolysosome numbers per cell area

  • Assess morphological features of autophagic structures

• Functional autophagy assays:

  • Long-lived protein degradation assays

  • Autophagic cargo receptor analysis

  • Selective autophagy substrate degradation

Research has shown that HOXA11-AS knockdown increases cellular autophagy in ovarian cancer cells, while adding the autophagy inhibitor 3-methyladenine (3-MA) reduces the anti-tumor properties of HOXA11-AS knockdown . This experimental approach effectively delineates the functional relationship between HOXA11-AS and autophagy in cancer progression.

How should researchers approach multiplex analysis when studying HOXA11 in relation to other biomarkers?

For effective multiplex analysis:

• Antibody panel design considerations:

  • Select antibodies raised in different host species to avoid cross-reactivity

  • Ensure compatible fixation requirements across all targets

  • Validate each antibody individually before multiplexing

• Fluorophore selection strategies:

  • Choose fluorophores with minimal spectral overlap

  • Implement appropriate compensation controls

  • Consider brightness hierarchy (assign brightest fluorophores to least abundant targets)

• Sequential staining approaches:

  • Use tyramide signal amplification for sequential detection

  • Implement heat-mediated antibody stripping between rounds

  • Validate epitope integrity after stripping procedures

• Analysis considerations:

  • Use spectral unmixing for complex panels

  • Implement automated quantification algorithms

  • Validate colocalization using appropriate statistical methods

Multiplex approaches are particularly valuable when investigating HOXA11's relationship with autophagy-related proteins or when assessing its expression alongside cell cycle regulators in cancer contexts.

What strategies can resolve inconsistent Western blot results when detecting HOXA11?

When facing inconsistent Western blot results:

• Sample preparation optimization:

  • Standardize protein extraction buffers (include DTT or β-mercaptoethanol)

  • Implement phosphatase/protease inhibitor cocktails

  • Maintain consistent sample preparation temperature (4°C)

• Gel electrophoresis parameters:

  • Optimize acrylamide percentage based on target MW (30kDa observed for HOXA11)

  • Standardize loading amounts (15-30μg total protein)

  • Include molecular weight markers with appropriate range

• Transfer and detection optimization:

  • Test different membrane types (PVDF vs. nitrocellulose)

  • Optimize transfer conditions (time, voltage, buffer composition)

  • Implement appropriate blocking agents (5% BSA or milk)

  • Test different antibody dilutions within recommended range (1:500 - 1:1000)

• Controls and normalization:

  • Include positive controls (mouse colon, rat uterus, rat kidney)

  • Implement loading controls appropriate for experimental context

  • Consider strip-and-reprobe approaches with caution

When troubleshooting, remember that the observed molecular weight for HOXA11 (30kDa) differs slightly from the calculated weight (34kDa) , which may impact band identification.

How can researchers validate that their experimental observations are specific to HOXA11-AS rather than related HOX genes?

To ensure specificity to HOXA11-AS versus related HOX genes:

• Transcript validation approaches:

  • Design PCR primers spanning unique regions or exon junctions

  • Implement northern blot with specific probes

  • Validate through RNA-seq with appropriate bioinformatic filters

• Knockdown specificity assessment:

  • Design multiple siRNA/shRNA constructs targeting unique regions

  • Validate knockdown efficiency at both RNA and protein levels

  • Assess expression of related HOX genes after knockdown

• Overexpression controls:

  • Use vectors containing full-length, sequence-verified HOXA11-AS

  • Include empty vector controls

  • Monitor related HOX gene expression after overexpression

• Functional rescue experiments:

  • Perform phenotype rescue experiments using HOXA11-AS constructs

  • Implement domain-specific mutations to identify functional regions

  • Use heterologous expression systems to assess function

Studies examining HOXA11-AS in ovarian cancer have documented expression differences using both R package analysis of public datasets (GSE18520) and experimental qRT-PCR validation across multiple cell lines (SKOV3, OVCAR3, A2780, and IOSE-80) , demonstrating the importance of multiple validation approaches.

What emerging technologies show promise for more precise characterization of HOXA11 function in development and disease?

Several cutting-edge technologies offer new avenues for HOXA11 research:

• CRISPR-based approaches:

  • CRISPRi/CRISPRa for endogenous gene modulation

  • CRISPR screens to identify synthetic lethal interactions

  • Base editing for introducing specific mutations in regulatory regions

• Single-cell technologies:

  • Single-cell RNA-seq to capture heterogeneity in HOXA11 expression

  • Single-cell proteomics to correlate transcript and protein levels

  • Spatial transcriptomics to map expression in tissue contexts

• Proximity labeling methods:

  • BioID or APEX2 fusion proteins to identify protein interactors

  • Chromatin-focused proximity labeling to map genomic targets

  • RNA-focused proximity labeling to identify RNA-protein interactions

• Advanced imaging techniques:

  • Super-resolution microscopy for subcellular localization

  • Live-cell imaging of tagged HOXA11 to track dynamics

  • Correlative light and electron microscopy for structural context

Studies already suggest HOXA11-AS influences critical cellular processes including autophagy regulation and cisplatin resistance , highlighting the value of implementing these emerging technologies to further dissect molecular mechanisms.

What methodological considerations are essential when studying HOXA11's role in regulating sensitivity to reactive oxygen species?

Research has begun exploring HOXA11-AS's relationship with reactive oxygen species (ROS) sensitivity in glioma . When investigating this relationship:

• ROS detection and quantification:

  • Select appropriate fluorescent probes (DCF-DA, DHE, MitoSOX)

  • Implement flow cytometry for population analysis

  • Use live-cell imaging to capture dynamic ROS changes

• Oxidative stress manipulation:

  • Test multiple ROS-inducing agents (H₂O₂, paraquat, menadione)

  • Implement antioxidant controls (NAC, catalase, GSH)

  • Establish dose-response relationships

• Downstream pathway analysis:

  • Assess activation of redox-sensitive transcription factors (Nrf2, NF-κB)

  • Measure oxidative damage markers (8-oxo-dG, protein carbonylation)

  • Evaluate cell death pathways (apoptosis, ferroptosis, necroptosis)

• In vivo validation approaches:

  • Implement xenograft models with HOXA11-AS manipulation

  • Use genetic models with altered antioxidant capacity

  • Measure oxidative stress biomarkers in tissues

These methodological considerations enable robust investigation of HOXA11-AS's role in modulating cellular responses to oxidative stress, a mechanism potentially relevant to both tumor progression and therapeutic resistance.